Watchlist Price Alert

CervoMed Inc. (CRVO)

NASDAQ: CRVO · Real-Time Price · USD

8.78

0.14 (1.62%)

At close: May 16, 2025, 3:59 PM

8.72

-0.69%

After-hours: May 16, 2025, 05:51 PM EDT

1.62% (1D)

Bid	8.72
Market Cap	76.41M
Revenue (ttm)	3.29M
Net Income (ttm)	-18.67M
EPS (ttm)	-2.02
PE Ratio (ttm)	-4.35
Forward PE	-3.99
Analyst	Buy

Ask	9
Volume	75,167
Avg. Volume (20D)	4,770,535
Open	8.60
Previous Close	8.64
Day's Range	8.64 - 8.89
52-Week Range	1.80 - 24.80
Beta	-0.25

About CRVO

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol CRVO

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for CRVO stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Earnings Surprise

CervoMed has released their quartely earnings on May 12, 2025:

Revenue of $1.92M misses estimates by $42.51K, with -18.30% YoY decline.

EPS of -0.56 exceeds estimates by 0.06, with -36.59% YoY decline.

Why Price Moved

1 month ago

+36.07%

CervoMed shares are trading higher after the compa... Unlock content with Pro Subscription

2 months ago

+3.2%

CervoMed shares are trading higher after Canaccord Genuity raised its price target on the stock from $12 to $21. Several firms also maintained Buy ratings on the stock.

News

4 days ago · zacks.com

CervoMed Inc. (CRVO) Reports Q1 Loss, Tops Revenue Estimates

CervoMed Inc. (CRVO) came out with a quarterly loss of $0.56 per share versus the Zacks Consensus Estimate of a loss of $0.60. This compares to loss of $0.41 per share a year ago.

1 month ago · seekingalpha.com

Biotech Stocks Q1 2025 Recap: Winners And Underperformers

Investing in biotech can be highly rewarding but is fraught with risks; understanding past catalysts can help investors make informed decisions and minimize downside risk. CervoMed Inc. surged over 30...

1 month ago · seekingalpha.com

CervoMed: Extension Study Data In Dementia With Lewy Bodies Is Potentially Exciting, With Caveats

CervoMed's stock surged more than 400% after interim data showed significant improvement with a new batch of neflamapimod in treating Dementia with Lewy Bodies. The recent interim readout deserves exc...